Success from Scratch

Accepting the biochallenge and permanent
looking for new opportunities

A Success Story

1998

Aenorasis is established

1998-2006

At the time, the business involved Medical Devices (Pharma Infusion Pumps), Diagnostics (ThinPrep Pap Test and Laboratory Sector) and Pharmaceuticals

2006

On 1 March 2006, Aenorasis embarks on a business partnership with Hospira.

2008

At a time when biosimilars were just beginning to grow in the global market, Aenorasis started from ground zero and launched Epoetin Zeta, the first biosimilar ever in Greece, in the haematology, oncology and nephrology specialties

2011

Filgrastim (oncology/haematology), a new biosimilar added to our portfolio

2015

A new challenge in a new therapeutic area. Aenorasis launched the 1st biosimilar mAb, infliximab, in the Greek market. It was the first biosimilar monoclonal antibody to be approved in the EU for use in rheumatology, gastroenterology and dermatology, segments in which Aenorasis had no previous experience.

2015

Hospira Inc. was bought out by Pfizer Inc., USA. Aenorasis extends the agreement of sole distribution for Pfizer products in Greece

2017

2 years after the launch of infliximab, Aenorasis held approximately 13% MS in volume and was the 3rd brand (in the total market of biologics) with a 43% share in the market for infliximab. This was an even more challenging project, given the different culture and approach of rheumatologists and gastroenterologists towards biosimilars (IQVIA DATA)

We are Aenorasis

Starting from scratch and faced with very challenging competition from several established companies with successful products, we have created our own success story

The biochallenge

The above are prescription drugs which should only be used as instructed by the healthcare professional and as approved in the National Organization for Medicines guidelines

ACTIVE INGREDIENT THERAPEUTIC CLASSIFICATION BUSINESS PARTNER
Epoetin Zeta Drug for Anaemia
Filgrastim Immunostimulative agent
Infliximab Immunosuppresant agent

With our proven track record of success in the exciting biosimilar business, we can ensure:

  • A high-performance and experienced commercial team of dedicated professionals who are keen to succeed
  • High compliance and safety standards
  • A state-of-the-art logistic infrastructure
  • A wide distribution network throughout Greece

A wide distribution network all around Greece

Our People, Our Strength

We have attracted a high-performance team of associates who are experienced in sales and marketing, come from big multinationals, have a proven track record and are able to serve the new biosimilar project

50 Sales & Marketing staff
25 Sales staff dedicated to biosimilars

Our People, Our Strength

Awards

Awards

Aenorasis received an important distinction in the Best Workplaces 2017 survey. In its first participation, Aenorasis was ranked by the established institute “Great Place to Work Hellas” among the top workplaces in Greece. This significant award acknowledges our efforts to develop and uphold a humane work environment, which reflects trust and respect for every member of Aenorasis.

Awards

For the second consecutive year, we have been awarded the GOLD prize in the Healthcare Business Awards for Aptima® mRNA HPV Test, the next generation test in the prevention of cervical cancer.

Awards

Aenorasis shone like “a diamond of the Greek economy” at the business excellence event Diamonds of the Greek Economy 2017, organized by New Times Publishing at the Hotel Grande Bretagne in Athens.

Awards

Aenorasis received the silver award in the Digital Campaign category of the Pharma Excellence Awards for the Endymion campaign.